Atezolizumab and Nab-paclitaxel

(asked on 31st January 2020) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the availability of atezolizumab with nab-paclitaxel on the NHS for breast cancer patients with PDL1 positive metastatic triple negative breast cancer.


Answered by
Jo Churchill Portrait
Jo Churchill
Minister of State (Department for Work and Pensions)
This question was answered on 10th February 2020

Atezolizumab is not currently routinely available on the National Health Service for breast cancer patients with PD-L1-positive, triple-negative, advanced breast cancer. The National Institute for Health and Care Excellence (NICE) is currently developing recommendations on the use of atezolizumab for this indication through its appraisal programme and published its draft guidance for consultation in October 2019. NICE’s appraisal has been delayed while commercial discussions with the company, Roche, are ongoing. NICE will aim to publish its guidance on the use of atezolizumab as soon as possible following the completion of their commercial discussions. If NICE is able to recommend use of the drug following the commercial discussions, atezolizumab will be eligible for funding through the Cancer Drugs Fund from the point of NICE’s draft guidance. If NICE is able to recommend use of atezolizumab it will be routinely funded by NHS England and NHS Improvement for NHS patients in line with NICE’s recommendations.

Reticulating Splines